Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 9/2014

01-09-2014 | Microvascular Complications—Nephropathy (B Roshan, Section Editor)

Low-Protein Diet for Diabetic Nephropathy

Authors: Toshiki Otoda, Keizo Kanasaki, Daisuke Koya

Published in: Current Diabetes Reports | Issue 9/2014

Login to get access

Abstract

Diabetic nephropathy is the leading cause of progressive kidney disease, leading to end-stage renal disease and renal replacement therapy. Angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers have been considered effective at slowing the progression of kidney function deterioration. However, these drugs cannot sufficiently halt the progression of nephropathy to the extent that is required. A low-protein diet (LPD) is believed to be a nutritional intervention that may slow kidney disease progression. In fact, preclinical animal experiments have demonstrated excellent renoprotective effects of an LPD. However, in human clinical trials, analyses of the effects of protein restriction on diabetic nephropathy have not yet revealed consistently positive outcomes of this nutritional intervention. In this review, we analyze the potential renoprotective effects of an LPD on diabetic nephropathy and summarize the outcomes of clinical trials that have systematically investigated the efficacy of an LPD in diabetic nephropathy. In addition, we discuss some potential approaches associated with nutritional interventions to combat progressive kidney disease.
Literature
1.
Premen AJ. Protein-mediated elevations in renal hemodynamics: existence of a hepato-renal axis? Med Hypotheses. 1986;19:295–309.PubMedCrossRef
2.
Ueda J, Nakanishi H, Miyazaki M, Abe Y. Effects of glucagon on the renal hemodynamics in the dog. Jpn Circ J. 1977;41:991–8.PubMedCrossRef
3.
Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell. 2008;7:681–7.PubMedCentralPubMedCrossRef
4.
Tonshoff B, Kaskel FJ, Moore LC. Effects of insulin-like growth factor I on the renal juxtamedullary microvasculature. Am J Physiol. 1998;274:F120–8.PubMed
5.
Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994;45:598–604.PubMedCrossRef
6.
Martinez-Maldonado M, Benabe JE, Wilcox JN, Wang S, Luo C. Renal renin, angiotensinogen, and ANG I-converting-enzyme gene expression: influence of dietary protein. Am J Physiol. 1993;264:F981–8.PubMed
7.
Benabe JE, Fernandez-Repollet E, Tapia E, Luo C, Martinez-Maldonado M. Angiotensin II and catecholamines interaction in short-term low protein feeding. Kidney Int. 1993;44:285–93.PubMedCrossRef
8.
Benabe JE, Wang S, Wilcox JN, Martinez-Maldonado M. Modulation of ANG II receptor and its mRNA in normal rat by low-protein feeding. Am J Physiol. 1993;265:F660–9.PubMed
9.
Peters H, Border WA, Noble NA. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Int. 2000;57:1493–501.PubMedCrossRef
10.
Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–9.PubMedCrossRef
11.
Gonska T, Hirsch JR, Schlatter E. Amino acid transport in the renal proximal tubule. Amino Acids. 2000;19:395–407.PubMedCrossRef
12.
Sallstrom J, Carlstrom M, Olerud J, Fredholm BB, Kouzmine M, Sandler S, et al. High-protein-induced glomerular hyperfiltration is independent of the tubuloglomerular feedback mechanism and nitric oxide synthases. Am J Physiol Regul Integr Comp Physiol. 2010;299:R1263–8.PubMedCrossRef
13.
Mino M, Nakamura J, Nakamuta N, Morioka H, Morikawa Y, Okada T. Effects of low protein intake on the development of the remaining kidney in subtotally nephrectomized immature rats: apoptosis and epidermal growth factor. J Vet Med Sci/ Jpn Soc Vet Sci. 2007;69:247–52.CrossRef
14.
Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, Border WA. Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis. Proc Natl Acad Sci U S A. 1991;88:9765–9.PubMedCentralPubMedCrossRef
15.
Fukui M, Nakamura T, Ebihara I, Nagaoka I, Tomino Y, Koide H. Low-protein diet attenuates increased gene expression of platelet-derived growth factor and transforming growth factor-beta in experimental glomerular sclerosis. J Lab Clin Med. 1993;121:224–34.PubMed
16.
Nakamura T, Fukui M, Ebihara I, Tomino Y, Koide H. Low protein diet blunts the rise in glomerular gene expression in focal glomerulosclerosis. Kidney Int. 1994;45:1593–605.PubMedCrossRef
17.
Cottini EP, Gallina DL, Dominguez JM. Urea excretion in adult humans with varying degrees of kidney malfunction fed milk, egg or an amino acid mixture: assessment of nitrogen balance. J Nutr. 1973;103:11–9.PubMed
18.
Hruska KA, Saab G, Mathew S, Lund R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial. 2007;20:309–15.PubMedCrossRef
19.
Ciavarella A, Di Mizio G, Stefoni S, Borgnino LC, Vannini P. Reduced albuminuria after dietary protein restriction in insulin-dependent diabetic patients with clinical nephropathy. Diabetes Care. 1987;10:407–13.PubMedCrossRef
20.
Walker JD, Bending JJ, Dodds RA, Mattock MB, Murrells TJ, Keen H, et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet. 1989;2:1411–5.PubMedCrossRef
21.
Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991;324:78–84.PubMedCrossRef
22.••
National Kidney F. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis Off J Natl Kidney Found. 2012;60:850–86. These guidelines represent the most up-to-date recommendations on the management of diabetes and CKD.CrossRef
23.
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877–84.PubMedCrossRef
24.
Beck GJ, Berg RL, Coggins CH, Gassman JJ, Hunsicker LG, Schluchter MD, et al. Design and statistical issues of the Modification of Diet in Renal Disease Trial. The Modification of Diet in Renal Disease Study Group. Control Clin Trials. 1991;12:566–86.PubMedCrossRef
25.
Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW, et al. Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis Off J Natl Kidney Found. 2006;48:879–88.CrossRef
26.
Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet. 1991;337:1299–304.PubMedCrossRef
27.
Pijls LT, de Vries H, Donker AJ, van Eijk JT. The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant Off Publ Eur Dial Transp Assoc Eur Renal Assoc. 1999;14:1445–53.
28.
Meloni C, Morosetti M, Suraci C, Pennafina MG, Tozzo C, Taccone-Gallucci M, et al. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Renal Nutr Off J Coun Renal Nutr Natl Kidney Found. 2002;12:96–101.CrossRef
29.
Raal FJ, Kalk WJ, Lawson M, Esser JD, Buys R, Fourie L, et al. Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. Am J Clin Nutr. 1994;60:579–85.PubMed
30.
Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ. Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care. 1993;16:483–92.PubMedCrossRef
31.
Dussol B, Iovanna C, Raccah D, Darmon P, Morange S, Vague P, et al. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. J Renal Nutr Off J Coun Renal Nutr Natl Kidney Found. 2005;15:398–406.CrossRef
32.
Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62:220–8.PubMedCrossRef
33.
Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Renal Nutr Off J Coun Renal Nutr Natl Kidney Found. 2004;14:208–13.CrossRef
34.
Pijls LT, de Vries H, van Eijk JT, Donker AJ. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Eur J Clin Nutr. 2002;56:1200–7.PubMedCrossRef
35.
Gross JL, Zelmanovitz T, Moulin CC, De Mello V, Perassolo M, Leitao C, et al. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial. Diabetes Care. 2002;25:645–51.PubMedCrossRef
36.
Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis Off J Natl Kidney Found. 1998;31:954–61.CrossRef
37.
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124:627–32.PubMedCrossRef
38.•
Nezu U, Kamiyama H, Kondo Y, Sakuma M, Morimoto T and Ueda S. Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. 2013. BMJ Open 3:e002934. doi:10.​1136/​bmjopen-2013-002934. This meta-analysis found that an LPD significantly improved kidney function in patients with DN.
39.•
Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, et al. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med. 2013;173:1682–92. This large-scale observational study trial found that an LPD increased the incidence or progression of CKD among individuals with type 2 diabetes.PubMed
40.
Robertson L, Waugh N, and Robertson A . Protein restriction for diabetic renal disease. 2007 Cochrane Database Syst Rev. CD002181.
41.
Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:660–6.PubMed
42.
National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis Off J Natl Kidney Found. 2002;39:S1–266.
43.
The National Collaborating Centre for Chronic Conditions (UK). In Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care, London; 2008.
44.
Andrassy KM. Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney Int. 2013;84:622–3.PubMedCrossRef
45.
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.PubMedCrossRef
46.
Arimura E, Horiuchi M, Kawaguchi H, Miyoshi N, Aoyama K, Takeuchi T. Low-protein diet improves blood and urinary glucose levels and renal manifestations of diabetes in C57BLKS-db/db mice. Eur J Nutr. 2013;52:813–24.PubMedCrossRef
47.
Walser M, Hill S, Tomalis EA. Treatment of nephrotic adults with a supplemented, very low-protein diet. Am J Kidney Dis Off J Natl Kidney Found. 1996;28:354–64.CrossRef
48.
Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. 2006;147:4160–8.PubMedCrossRef
49.
Merforth S, Osmers A, Dahlmann B. Alterations of proteasome activities in skeletal muscle tissue of diabetic rats. Mol Biol Rep. 1999;26:83–7.PubMedCrossRef
50.
Gougeon R, Pencharz PB, Sigal RJ. Effect of glycemic control on the kinetics of whole-body protein metabolism in obese subjects with non-insulin-dependent diabetes mellitus during iso- and hypoenergetic feeding. Am J Clin Nutr. 1997;65:861–70.PubMed
51.
Gougeon R, Styhler K, Morais JA, Jones PJ, Marliss EB. Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes. Diabetes Care. 2000;23:1–8.PubMedCrossRef
52.
Mitch WE. Metabolic acidosis stimulates protein metabolism in uremia. Miner Electrolyte Metab. 1996;22:62–5.PubMed
53.
Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int Supp. 2005;S21–27.
54.
Mitch WE. Metabolic and clinical consequences of metabolic acidosis. J Nephrol. 2006;19 Suppl 9:S70–5.PubMed
55.
Kopple JD, Mehrotra R, Suppasyndh O, Kalantar-Zadeh K. Observations with regard to the National Kidney Foundation K/DOQI clinical practice guidelines concerning serum transthyretin in chronic renal failure. Clin Chem Lab Med CCLM / FESCC. 2002;40:1308–12.
56.
Blumenkrantz MJ, Kopple JD, Gutman RA, Chan YK, Barbour GL, Roberts C, et al. Methods for assessing nutritional status of patients with renal failure. Am J Clin Nutr. 1980;33:1567–85.PubMed
57.
Koya D, Haneda M, Inomata S, Suzuki Y, Suzuki D, Makino H, et al. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. Diabetologia. 2009;52:2037–45.PubMedCentralPubMedCrossRef
58.
Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 1985;27:58–65.PubMedCrossRef
59.
Borah MF, Schoenfeld PY, Gotch FA, Sargent JA, Wolfsen M, Humphreys MH. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int. 1978;14:491–500.PubMedCrossRef
60.
Gannon MC, Nuttall FQ, Westphal SA, Fang S, Ercan-Fang N. Acute metabolic response to high-carbohydrate, high-starch meals compared with moderate-carbohydrate, low-starch meals in subjects with type 2 diabetes. Diabetes Care. 1998;21:1619–26.PubMedCrossRef
61.
Solon-Biet SM, McMahon AC, Ballard JWO, Ruohonen K, Wu LE, Cogger VC, et al. The Ratio of Macronutrients, Not Caloric Intake, Dictates Cardiometabolic Health, Aging, and Longevity in Ad Libitum-Fed Mice. Cell Metab. 2014;19:418–30.PubMedCrossRef
62.
Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng C-W, Madia F, et al. Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population. Cell Metab. 2014;19:407–17.PubMedCrossRef
63.
64.
Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.PubMedCrossRef
65.
Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151–71.PubMedCrossRef
66.
Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem. 1998;273:14484–94.PubMedCrossRef
67.
Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121:2181–96.PubMedCentralPubMedCrossRef
68.
Yamahara K, Kume S, Koya D, Tanaka Y, Morita Y, Chin-Kanasaki M, et al. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J Am Soc Nephrol JASN. 2013;24:1769–81.CrossRef
69.
Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun. 2006;340:296–301.PubMedCrossRef
70.•
Ohkawa S, Yanagida M, Uchikawa T, Yoshida T, Ikegaya N, Kumagai H. Attenuation of the activated mammalian target of rapamycin pathway might be associated with renal function reserve by a low-protein diet in the rat remnant kidney model. Nutr Res. 2013;33:761–71. This animal study suggests that the preventive effect of an LPD on the proggression of renal failure is associated with attenuation of the activated mTOR/p70S6k pathway.PubMedCrossRef
71.
Della Torre S, Rando G, Meda C, Stell A, Chambon P, Krust A, et al. Amino acid-dependent activation of liver estrogen receptor alpha integrates metabolic and reproductive functions via IGF-1. Cell Metab. 2011;13:205–14.PubMedCrossRef
Metadata
Title
Low-Protein Diet for Diabetic Nephropathy
Authors
Toshiki Otoda
Keizo Kanasaki
Daisuke Koya
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 9/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0523-z

Other articles of this Issue 9/2014

Current Diabetes Reports 9/2014 Go to the issue

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Self-Antigen Expression in the Peripheral Immune System: Roles in Self-Tolerance and Type 1 Diabetes Pathogenesis

Psychosocial Aspects (KK Hood, Section Editor)

Use of Technology When Assessing Adherence to Diabetes Self-Management Behaviors

Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Interleukin-7 and Type 1 Diabetes

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Multifocal Electroretinography in Diabetic Retinopathy and Diabetic Macular Edema

Psychosocial Aspects (KK Hood, Section Editor)

Young Children with Type 1 Diabetes: Challenges, Research, and Future Directions
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits